Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Net Cash Flow (2016 - 2025)

Celldex Therapeutics has reported Net Cash Flow over the past 16 years, most recently at -$7.2 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$7.2 million for Q4 2025, up 10.9% from a year ago — trailing twelve months through Dec 2025 was $515000.0 (up 107.97% YoY), and the annual figure for FY2025 was $515000.0, up 107.97%.
  • Net Cash Flow for Q4 2025 was -$7.2 million at Celldex Therapeutics, down from $13.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for CLDX hit a ceiling of $80.3 million in Q1 2024 and a floor of -$72.3 million in Q2 2024.
  • Median Net Cash Flow over the past 5 years was -$6.7 million (2023), compared with a mean of -$748250.0.
  • Biggest five-year swings in Net Cash Flow: crashed 933.3% in 2023 and later skyrocketed 304.94% in 2025.
  • Celldex Therapeutics' Net Cash Flow stood at -$33.0 million in 2021, then surged by 132.83% to $10.8 million in 2022, then increased by 26.13% to $13.7 million in 2023, then tumbled by 158.79% to -$8.0 million in 2024, then rose by 10.9% to -$7.2 million in 2025.
  • The last three reported values for Net Cash Flow were -$7.2 million (Q4 2025), $13.0 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.